Month: February 2025

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCOLusvertikimab achieved statistical significance on the primary and secondary endpoints in moderate to severe active ulcerative colitis (UC) patients during the 10-week induction period of treatment in the randomized, double-blind CoTikiS Phase 2 study. These results were presented in the Top 10 congress highlights oral plenary session at ECCO 2025. Lusvertikimab demonstrated high rates of clinical and endoscopic remission after 10 weeks of treatment, along with clinically meaningful histological improvement and Histo-Endoscopic Mucosal Improvement (HEMI) rates. Treatment with Lusvertikimab significantly reduced fecal calprotectin (FCP) after 10 weeks of treatment, an objective biomarker of mucosal...

EXOSENS STRENGTHENS ITS POSITION AS A KEY SUPPLIER TO SENOP FOR NIGHT VISION IMAGE INTENSIFIER TUBES HIGHLIGHTING INCREASING DEMAND FOR NIGHT VISION GOGGLES PRESS RELEASEMÉRIGNAC, FRANCE – FEBRUARY, 24th 2025Exosens announces that Senop, a Finnish provider of high-tech optronic solutions including night vision goggles, has placed several significant orders for its Photonis white phosphor 4G intensifier tubes, to be delivered over 2025. Third contracts signed with Senop since 2021 confirming Exosens position as the strategic supplier of image intensifier tubes for Baltic and Nordic countries underscoring the potential for material new sales in this area. Rising demand for Night Vision goggles driven by increased military budgets and demonstrated criticality of night vision. Exosens continue to fully benefit from this increasing demand...

Press releaseGlobe Telecom, Nokia collaborate on network APIs to provide banks with enhanced security #MWC25Globe tests Nokia’s Network Exposure Platform (NEP) to enhance security in financial services.24 February 2025Espoo, Finland – Globe Telecom, one of the largest telecommunications operators in the Philippines with over 60 million subscribers, today announced that it is collaborating with Nokia to provide banks and other enterprises with enhanced security through the utilization of network Application Programming Interfaces (APIs). Globe Telecom, which already uses a host of other Nokia solutions including 5G RAN, is testing Nokia’s Network Exposure Platform in expanding and simplifying the number of APIs available to the operator and its enterprise partners to enable the creation of security-focused applications. APIs provide...

Frontline plc.’s preliminary fourth quarter 2024 results will be released on Friday February 28, 2025, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at www.frontlineplc.cy ahead of the conference call. In order to attend the conference call you may do one of the following: a. WebcastGo to the Investor Relations section at www.frontlineplc.cy and follow the “Webcast” link, or access directly from the link below. Frontline plc Q4 2024 Webcast b. Conference CallParticipants will need to register online prior to the conference call via the link below. Dial-in details will be available when registered.             Frontline plc Q4 2024 Conference Call A Q&A session will be held after the teleconference/webcast....

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars in US Strengthens US immunology portfolio and increases access to biologics for patients suffering from chronic inflammatory diseases, such as psoriasis and psoriatic arthritis Meeting a variety of patient needs, Pyzchiva® offers full suite of dosing options and extended stability compared with reference medicineBasel, February 24, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab-ttwe) in the US. From today, the medicine is commercially available to patients across the US. Developed by Samsung Bioepis Co., Ltd., and commercialized by Sandoz, Pyzchiva®...

LONGBOAT KEY, Fla., Feb. 23, 2025 (GLOBE NEWSWIRE) — Rumble (NASDAQ:RUM), the video-sharing platform and cloud services provider, today released the following statement from CEO and Chairman Chris Pavlovski regarding the recent appointment of content creator Dan Bongino as Deputy Director of the FBI in the Trump Administration: “Dan Bongino is a pioneer and a free speech warrior, and it has been an honor to host his content on Rumble. More than just that, he has been a mentor to me personally through these important years of Rumble’s explosive growth, and he has become a dear friend I will have for life. Dan was one of the first major creators to move his content to Rumble in 2020 and has set many livestreaming records ever since. He believes strongly in the innate human right to self-expression—in fact, he’s turned it into an...

NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast’s largest shareholder, to its Board of Directors. Dr. George founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development. Dr. George brings to the Board his background as a medical scientist with unique operational experience having built a start-up company in the medical field and turning it into a highly-efficient multi-billion-dollar commercial organization. Mesoblast Founder and Chief Executive Dr. Silviu Itescu said, “Greg’s unique operational skills and insights will provide tremendous value as Mesoblast transitions to become...

Perth, Feb. 24, 2025 (GLOBE NEWSWIRE) — PERSEUS MINING’S HALF YEAR PROFIT UP 22% TO US$201M, NET CASH & BULLION UP US$117M TO US$704M Perth, Western Australia/ February 24, 2025/Mid-tier, gold producer, developer and explorer, Perseus Mining Limited (ASX/TSX:PRU) is pleased to report material improvements across all key financial metrics including revenue, EBITDA, profit after tax, operating cash flow and net cash position in its Interim Financial Report for the six months ending December 31, 2024 (H1 FY25). HIGHLIGHTSRevenue increased to US$581.8 million, up 19% on prior corresponding period EBITDA(1) up 26% to US$352.7 million on prior corresponding period Profit after Tax increased to US$201 million up 22% on prior corresponding period Operating cash flow increased to US$248 million, up 17% on prior corresponding period Total...

• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in solid tumors NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced details of its poster presentation at the American Association for Cancer Research (AACR)-IO conference taking place February 23-26, 2025, in Los Angeles, California. Poster Presentation DetailsTitle: A TGF-β-directed peptide vaccine induces T cell activation & drives anti-tumor activity by modulating the architecture of the tumor microenvironmentPoster number: B117Presenter: Matteo Bocci, PhD, Senior ScientistDate and time: Tuesday, February 25, 2025, 1:45-4:00 PM PSTLocation:...